骨巨细胞瘤患者血清指标、影像学表现与临床分期的关系

Relationship between serum indicators,imaging manifestations,and clinical staging in patients with giant cell tumor of bone

目的探讨骨巨细胞瘤患者血清Ⅰ型胶原蛋白交联N端肽(NTx)、血管内皮生长因子(VEGF)及影像学表现与临床病理学分期的关系。方法选取2018年1月至2022年12月烟台市烟台山医院确诊的73例骨巨细胞瘤患者作为病例组,健康体检志愿者80例作为对照组,对比两组研究对象的血清NTx、VEGF水平,病例组患者同时接受计算机断层扫描(CT)、磁共振成像(MRI)检查,并按照肿瘤病理学分期特征分层对比骨巨细胞瘤患者的血清NTx、VEGF水平及影像学特征的差异。血清NTx、VEGF水平对比假设检验方法为t检验,计数资料采用率(%)描述,对比假设检验方法为χ^(2)检验,以P<0.05为差异有统计学意义。结果病例组患者的血清NTx、VEGF[(28.61±5.93)nmol BCE/L、(411.3±93.5)pg/ml]水平显著高于对照组[(18.44±3.70)nmol BCE/L、(163.9±34.0)pg/ml,t=12.844、22.123,P<0.05];73例骨巨细胞瘤患者,根据Jaffe分期标准,Ⅰ期11例、Ⅱ期32例、Ⅲ期30例;Ⅰ期+Ⅱ期的骨巨细胞瘤患者的血清NTx、VEGF[(24.01±5.11)nmol BCE/L、(377.8±88.4)pg/ml]水平显著低于Ⅲ期患者[(35.20±5.67)nmol BCE/L、(459.3±75.0)pg/ml,t=-8.799、-4.118,P<0.05]。结论骨巨细胞瘤患者的血清NTx,VEGF水平较正常人群显著的增高并且与病理学分期、影像学特征有关,对于判断患者病情有重要价值。

Objective To investigate the relationship between serum typeⅠcollagen cross-linked N-terminal peptide(NTx),vascular endothelial growth factor(VEGF),imaging findings and clinicopathological staging in patients with giant cell tumor of bone.Methods From January 2018 to December 2022,73 patients with giant cell tumor of bone in Yantai Mountain Hospital were selected as the case group,and 80 healthy volunteers were selected as the control group.Serum NTx and VEGF levels were compared between the two groups.At the same time,patients in the case group received computed tomography(CT)and magnetic resonance imaging(MRI)examinations.According to the staging characteristics of tumor pathology,the differences in serum NTx,VEGF levels and imaging features of patients with giant cell tumor of bone were stratified and compared.The t-test was used for the comparison of serum NTx and VEGF levels.Count data were described by rate(%)and the comparison hypothesis was tested byχ^(2) test,with P<0.05 as the difference was statistically significant Results The serum levels of NTx and VEGF[(28.61±5.93)nmol BCE/L and(411.3±93.5)pg/ml]in the case group were significantly higher than those in the control group[(18.44±3.70)nmol BCE/L and(163.9±34.0)pg/ml,t=12.844,t=22.123,P<0.05].In 73 patients with giant cell tumors of bone,according to Jaffe staging criteria,there were 11 cases in stageⅠ,32 cases in stageⅡ,and 30 cases in stageⅢ.The serum NTx and VEGF[(24.01±5.11)nmol BCE/L and(377.8±88.4)pg/ml]levels in patients with stageⅠ+stageⅡgiant cell tumors were significantly lower than those in stageⅢpatients[(35.20±5.67)nmol BCE/L and(459.3±75.0)pg/ml,t=-8.799,-4.118,P<0.05].Conclusion The serum levels of NTx and VEGF in patients with giant cell tumor of bone are significantly higher than those in the normal population.There are significant differences in NTx,VEGF,and imaging characteristics among patients with giant cell tumor of bone at different pathological stages,which is of great value in determining the patient’s condition.